Fellowship in Action: Our First In-House Manufacturing Run

Earlier this year, Vor Bio dosed its first patient with VCAR33ALLO, a transplant donor-derived CAR-T targeting CD33 in AML patients. VCAR33ALLO is manufactured at our in-house facility in Cambridge, MA, and Voracians were directly involved in every part of the process. We spoke with a few of the team members who participated in this momentous […]

Read More… from Fellowship in Action: Our First In-House Manufacturing Run

From Concept to Clinical Trial Results: A Conversation with Glen Raffel, MD, PhD, VP of Clinical Research & Development

As we continue to share results from our first clinical trial, VBP101, we checked in with our Vice President of Clinical Research & Development, Glen Raffel, MD, PhD, to find out what it’s like seeing this concept progress from an idea to a clinical trial where we are now seeing results in patients who have received this drug candidate. […]

Read More… from From Concept to Clinical Trial Results: A Conversation with Glen Raffel, MD, PhD, VP of Clinical Research & Development